Gilead Sciences (GILD) Times Interest Earned (2009 - 2026)
Gilead Sciences' (GILD) quarterly Times Interest Earned came in at 42.08 in Q2 2026, down 532.04% on a YoY basis from 9.74 in Q2 2025, and down 490.54% quarter-over-quarter from 10.78 in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) Times Interest Earned (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Times Interest Earned for 18 consecutive years, with 42.08 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Times Interest Earned fell 532.04% year-over-year to 42.08; the trailing twelve-month figure through Jun 2026 stood at 2.5 (down 131.11% YoY), and the FY2025 full-year result was 9.79, up 475.33% from the prior year.
- Times Interest Earned fell to 42.08 in Q2 2026 per GILD's latest filing, from 10.78 in the prior quarter.
- Across five years, Times Interest Earned topped out at 13.0 in Q3 2025 and bottomed at 42.08 in Q2 2026.
- Historically, Times Interest Earned has averaged 4.42 across 5 years, with a median of 8.49 in 2025.
- The sharpest annual moves came in 2023 and 2026: Times Interest Earned soared 795.59% in 2023, then plunged 532.04% in 2026.
- Over 5 years, Times Interest Earned stood at 10.03 in 2022, then sank by 36.23% to 6.4 in 2023, then soared by 53.94% to 9.85 in 2024, then retreated by 20.99% to 7.78 in 2025, then sank by 640.86% to 42.08 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered 42.08, 10.78, and 7.78 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | -0.08 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.08 |
| Mar 31, 2026 | 10.78 |
| Dec 31, 2025 | 7.78 |
| Sep 30, 2025 | 13.00 |
| Jun 30, 2025 | 9.74 |
| Mar 31, 2025 | 8.60 |
| Dec 31, 2024 | 9.85 |
| Sep 30, 2024 | 3.73 |
| Jun 30, 2024 | 11.16 |
| Mar 31, 2024 | -17.02 |
| Dec 31, 2023 | 6.40 |
| Sep 30, 2023 | 11.31 |
| Jun 30, 2023 | 7.24 |
| Mar 31, 2023 | 7.41 |
| Dec 31, 2022 | 10.03 |
| Sep 30, 2022 | 12.39 |
| Jun 30, 2022 | 8.38 |
| Mar 31, 2022 | 0.83 |
| Dec 31, 2021 | 3.95 |
| Sep 30, 2021 | 15.37 |